Yost Capital Management LP Makes New Investment in Maravai LifeSciences Holdings, Inc. $MRVI

Yost Capital Management LP acquired a new position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 126,056 shares of the company’s stock, valued at approximately $410,000. Maravai LifeSciences accounts for 0.6% of Yost Capital Management LP’s portfolio, making the stock its 13th biggest holding.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Monaco Asset Management SAM increased its stake in shares of Maravai LifeSciences by 315.0% in the third quarter. Monaco Asset Management SAM now owns 3,656,337 shares of the company’s stock worth $10,494,000 after acquiring an additional 2,775,372 shares during the period. Tejara Capital Ltd increased its stake in shares of Maravai LifeSciences by 23.1% in the fourth quarter. Tejara Capital Ltd now owns 3,020,209 shares of the company’s stock worth $9,816,000 after acquiring an additional 566,768 shares during the period. Geode Capital Management LLC increased its stake in shares of Maravai LifeSciences by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 2,848,105 shares of the company’s stock worth $9,259,000 after acquiring an additional 34,447 shares during the period. State Street Corp increased its stake in shares of Maravai LifeSciences by 1.1% in the fourth quarter. State Street Corp now owns 2,414,249 shares of the company’s stock worth $7,846,000 after acquiring an additional 27,219 shares during the period. Finally, Goldman Sachs Group Inc. increased its stake in shares of Maravai LifeSciences by 28.1% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,014,214 shares of the company’s stock worth $6,546,000 after acquiring an additional 442,059 shares during the period. Institutional investors and hedge funds own 50.25% of the company’s stock.

Maravai LifeSciences Price Performance

Shares of NASDAQ MRVI opened at $4.98 on Monday. The company’s 50-day simple moving average is $4.06 and its 200-day simple moving average is $3.65. Maravai LifeSciences Holdings, Inc. has a 52-week low of $1.99 and a 52-week high of $5.30. The firm has a market cap of $1.29 billion, a price-to-earnings ratio of -7.01 and a beta of 0.71. The company has a quick ratio of 4.96, a current ratio of 5.91 and a debt-to-equity ratio of 0.72.

Maravai LifeSciences (NASDAQ:MRVI) last announced its earnings results on Thursday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.06. Maravai LifeSciences had a negative net margin of 51.07% and a negative return on equity of 17.87%. The business had revenue of $65.84 million for the quarter, compared to analyst estimates of $53.00 million. Equities analysts predict that Maravai LifeSciences Holdings, Inc. will post -0.2 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Wall Street Zen upgraded shares of Maravai LifeSciences from a “hold” rating to a “buy” rating in a research note on Saturday, May 23rd. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $6.00 price target on shares of Maravai LifeSciences in a research report on Friday, May 8th. UBS Group restated a “reduce” rating on shares of Maravai LifeSciences in a research report on Wednesday, June 3rd. Wells Fargo & Company raised their price target on shares of Maravai LifeSciences from $4.50 to $5.50 and gave the company an “overweight” rating in a research report on Friday, May 8th. Finally, Weiss Ratings upgraded shares of Maravai LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 29th. Three research analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $5.50.

Insider Activity

In other news, General Counsel Kurt Oreshack sold 25,000 shares of Maravai LifeSciences stock in a transaction dated Tuesday, June 9th. The shares were sold at an average price of $5.06, for a total value of $126,500.00. Following the sale, the general counsel owned 360,767 shares in the company, valued at $1,825,481.02. This trade represents a 6.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.49% of the stock is currently owned by company insiders.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.